Skip to main content

Cellbricks

HardwareBerlin, GermanyFounded 2017· One of 1637 Hardware companies tracked by AMPulse

Developing implantable vascularized human tissue grafts via proprietary high-resolution light-based 3D bioprinting.

CEO / Founder
Alexander Leutner and Simon MacKenzie (Co-CEOs)
Team Size
11-50
Stage
Active
Total Funding
$10.8M
Latest Round
Seed
Key Investors
Silicon Roundabout Ventures (lead); SPRIND; ACT Venture Partners; B.value

Technology & Products

Key Products

Biofabricated tissue implants for soft tissue repair, wound healing, and trauma care.

Technical position · AMPulse analysis

Proprietary DLP-based bioprinting process; interdisciplinary expertise in tissue engineering; validated through zero-gravity R&D and animal trials.

Patent position

Cellbricks filed 15 patent families across all years, compared with 5 for Allevi and 52 for CELLINK. AMPulse analysis

Filing momentum
6 families filed 2022–2024, 6 in 2019–2021 (0%); all tracked AM filings in the same offices -19%
Filed in
WO 40%EP 33%US 27%CN 7%
Named competitors, AM patent families
Allevi 5CELLINK 52

15 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Enables the production of vascularized human tissues and organ models with high resolution, reducing the gap between lab-grown tissues and clinical implants.

How They Differentiate

Focus on high-resolution vascularization and scalable tissue therapeutics using tailor-made biomaterials.

Market & Competition

Target Customers

Regenerative medicine patients and researchers

Industry Verticals

Medical; Biotechnology; Regenerative Medicine

Competitors

Allevi, Regemat 3D, Cellink

Growth & Milestones

Growth Metrics

€10M raise in March 2026; Positive animal trials in April 2025; Team of 20-30 from 14 nations

Major Milestones

Founded in 2017; Earliest operations as Cellbricks GmbH in 2018; Received Bayer G4A and BMBF grants; Closed EUR 5M Seed II round; Established Boston expansion hub; Initiated in vivo studies for liver patches and breast implants; Zero-gravity bioprinting tests with BIH/Charité; Positive animal trials in April 2025; €10M funding round in March 2026

Notable Customers

Charité – Universitätsmedizin Berlin; Berlin Institute of Health (BIH); Robert Koch Institute (RKI); Bayer; TissUse GmbH; Technische Universität Berlin (TU Berlin); Max Delbrück Center for Molecular Medicine (MDC); Leibniz Institute of Polymer Research Dresden; Orthopaedic University Hospital Heidelberg

https://cellbricks-therapeutics.com

AM patents

AM-relevant patents linked to this company.

Patents
16
Granted
3
Families
15

Leading domains: process (16), application (6)

Filings by year: 2023: 3 · 2022: 3 · 2019: 6 · 2018: 4

  1. POLYPEPTIDE FOR 3D PRINTING INK04501955 · EP
  2. METHOD FOR PRODUCING A CELL CULTURE INSERT HAVING AT LEAST ONE MEMBRANE112424331 · CN
  3. 3D SCAFFOLD CONSISTING OF A BIOCOMPATIBLE POLYMER WITH A COLONISATION VOLUME OPEN AT THE TOP FOR BIOLOGICAL CELLS, AND WITH A CANAL-TYPE VESSEL SURROUNDING THE COLONISATION VOLUME04065372 · EP
  4. Method for producing 3D, biocompatible polymer scaffold with a cell-filled cavity11993767 · US
  5. 3D SCAFFOLD CONSISTING OF A BIOCOMPATIBLE POLYMER WITH A COLONISATION VOLUME OPEN AT THE TOP FOR BIOLOGICAL CELLS, AND WITH A CANAL-TYPE VESSEL SURROUNDING THE COLONISATION VOLUME2021104570 · WO

Funding rounds

  • Seed€7M2026-03Source: Tech.eu - March 25, 2026

Why this company matters

AMPulse analysis, not a company disclosure

Cellbricks occupies a distinctive position in the bioprinting landscape by focusing on high-resolution vascularization of multi-cell-type tissues, a critical bottleneck in moving lab-grown constructs toward clinical implants. Unlike many bioprinting firms that emphasize cell-laden hydrogel extrusion, Cellbricks uses a proprietary DLP-based vat photopolymerization process to create complex, perfusable vascular networks within tissue grafts. This approach aims to solve the oxygen and nutrient diffusion limits that constrain the size and viability of engineered tissues.

The company's core technology is a light-based bioprinting platform that builds structures layer by layer using photocurable bioinks. By integrating multiple cell types and biomaterials in a single print, Cellbricks can produce constructs that more closely mimic native tissue architecture. Its product pipeline targets soft tissue repair, wound healing, and trauma care, with specific programs including liver patches and breast implants. The company has validated its process through zero-gravity experiments with Charité and the Berlin Institute of Health, as well as positive animal trials completed in April 2025.

Cellbricks serves researchers and clinicians in regenerative medicine, biotechnology, and medical device development. Its notable partners include Charité – Universitätsmedizin Berlin, the Robert Koch Institute, Bayer, TissUse GmbH, and several German research institutes. The company has raised approximately €10 million in total funding, including a €5 million Seed II round and a €10 million round closed in March 2026, with backing from Silicon Roundabout Ventures, SPRIND, ACT Venture Partners, and B.value. It operates from Berlin and a Boston expansion hub, with a team of 20-30 people from 14 nations.

The company's strategic moat rests on its proprietary DLP bioprinting process and interdisciplinary expertise in tissue engineering, supported by nine patent families covering high-resolution light-based bioprinting and specialized bioinks. However, it faces competition from established bioprinting hardware makers such as Allevi, Regemat 3D, and Cellink, which offer broader platforms for academic and pharmaceutical customers. Cellbricks' differentiation lies in its focus on scalable, vascularized tissue therapeutics rather than general-purpose bioprinting tools, but the path from animal trials to regulated clinical products remains long and capital-intensive.